Oncology therapy developer Recludix Pharma raised $60m in an Access Biotechnology-backed round while Stripe took part in digital payment technology developer Imprint's $38m series A.

Funding

Recludix Pharma, a US-based developer of small molecule cancer and inflammatory disease therapeutics, publicly launched yesterday with $60m in series A funding from investors including Access Biotechnology, a VC subsidiary of conglomerate Access Industries. Venture capital firms New Enterprise Associates and Westlake Village BioPartners also contributed to the round.

US-based digital payment and rewards technology developer Imprint raised $38m in series A funding from investors including online payment processor Stripe yesterday. The round was led by VC firm Kleiner…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn